| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Caftaric acid targets multiple pathways involved in oxidative stress, inflammation, and cancer. It inhibits protein-protein interactions mediated by Src-family kinases. Its antioxidant activity is attributed to its ability to scavenge free radicals and protect against oxidative stress. Its anti-inflammatory effects are mediated through the modulation of cellular signaling pathways. The compound's anti-carcinogenic properties suggest potential for cancer prevention. Its ability to inhibit Src-family kinases indicates potential for modulating cell signaling pathways involved in proliferation and survival.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that caftaric acid exhibits potent antioxidant, anti-inflammatory, and anti-carcinogenic properties. It scavenges free radicals and protects against oxidative stress in various cell-based models. The compound inhibits protein-protein interactions mediated by Src-family kinases. It has anti-mutagenicity. Its ability to modulate cellular signaling pathways contributes to its biological activities. The compound's activity profile makes it a valuable tool for studying oxidative stress, inflammation, and cancer.
|
| ln Vivo |
In vivo, caftaric acid has been shown to prevent liver toxicity and oxidative stress when administered before methamphetamine injections. Its antioxidant and anti-inflammatory properties suggest potential therapeutic applications in various diseases. However, comprehensive in vivo efficacy and safety studies are needed to fully evaluate its therapeutic potential. The compound's natural occurrence in various foods supports its potential as a nutraceutical agent.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for caftaric acid typically involve measuring its antioxidant activity using DPPH, ABTS, or FRAP assays. The compound is incubated with the radical-generating system, and the decrease in absorbance is measured spectrophotometrically to calculate the scavenging activity and IC₅₀ values. The inhibition of Src-family kinase-mediated protein-protein interactions can be assessed using cell-free assays with purified proteins. These assays provide quantitative data on the compound's direct effects on its molecular targets.
|
| Cell Assay |
In vitro cell-based assays for caftaric acid use various cell lines to study its biological activities. For antioxidant studies, cells are exposed to oxidative stress (e.g., H₂O₂) and treated with caftaric acid, and parameters such as cell viability (MTT or CCK-8 assays), reactive oxygen species levels (DCFH-DA staining), and antioxidant enzyme activities are assessed. For anti-inflammatory studies, macrophages or other immune cells stimulated with LPS are used, and the production of inflammatory cytokines is measured by ELISA. For anti-carcinogenic studies, cancer cell lines are used, and cell proliferation and apoptosis are assessed.
|
| Animal Protocol |
In vivo animal studies for caftaric acid would likely employ models of oxidative stress, inflammation, and cancer. For antioxidant studies, models such as methamphetamine-induced liver toxicity are used, and parameters such as liver function markers, oxidative stress markers, and histopathology of liver tissues are assessed. For anti-inflammatory studies, standard models such as carrageenan-induced paw edema are used. For anti-carcinogenic studies, models of chemical carcinogenesis are used, and the incidence and size of tumors are assessed. Pharmacokinetic studies in these models provide information about the compound's absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Caftaric acid has a molecular weight of 312.23 g/mol and a molecular formula of C₁₃H₁₂O₉. It is a hydroxycinnamic acid and a tartaric acid ester form of caffeic acid. The compound is a major dietary polyphenol present in various foods. It has been reported in Vitis longii, Hydrastis canadensis, and other organisms. It is also a metabolite found in or produced by Saccharomyces cerevisiae. The compound should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of caftaric acid has not been comprehensively evaluated in published studies. As a natural polyphenol found in various foods, it is generally considered to have low toxicity. The compound's ability to prevent liver toxicity and oxidative stress suggests a protective rather than toxic effect. The compound is classified as a research reagent and is not intended for human therapeutic use without further safety evaluation. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Caffeic acid is a hydroxycinnamic acid. It has been reported to be found in grapes (Vitis longii), Canadian ginseng (Hydrastis canadensis), and other organisms with relevant data. Caffeic acid is a metabolite found in or produced by the yeast Saccharomyces cerevisiae.
Caftaric acid is a hydroxycinnamic acid and a tartaric acid ester form of caffeic acid. It is a major dietary polyphenol present in various foods. The compound is an inhibitor of protein-protein interactions mediated by Src-family kinases and has anti-mutagenicity. It exhibits potent antioxidant, anti-inflammatory, and anti-carcinogenic properties. Caftaric acid is widely studied for its ability to scavenge free radicals, protect against oxidative stress, and modulate cellular signaling pathways. It has been reported in Vitis longii, Hydrastis canadensis, and other organisms. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C13H12O9
|
|---|---|
| Molecular Weight |
312.2290
|
| Exact Mass |
312.048
|
| CAS # |
67879-58-7
|
| PubChem CID |
6440397
|
| Appearance |
Off-white to yellow solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
618.2±55.0 °C at 760 mmHg
|
| Melting Point |
124-125ºC
|
| Flash Point |
236.3±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.694
|
| LogP |
1.14
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O(C(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])=O)[C@@]([H])(C(=O)O[H])[C@]([H])(C(=O)O[H])O[H]
|
| InChi Key |
SWGKAHCIOQPKFW-JTNORFRNSA-N
|
| InChi Code |
InChI=1S/C13H12O9/c14-7-3-1-6(5-8(7)15)2-4-9(16)22-11(13(20)21)10(17)12(18)19/h1-5,10-11,14-15,17H,(H,18,19)(H,20,21)/b4-2+/t10-,11-/m1/s1
|
| Chemical Name |
(2R,3R)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-3-hydroxybutanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~160.14 mM)
H2O : ~50 mg/mL (~160.14 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (80.07 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2028 mL | 16.0138 mL | 32.0277 mL | |
| 5 mM | 0.6406 mL | 3.2028 mL | 6.4055 mL | |
| 10 mM | 0.3203 mL | 1.6014 mL | 3.2028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
